Quantitative proteomic analysis for novel biomarkers of buccal squamous cell carcinoma arising in background of oral submucous fibrosis

Wen Liu¹, Lijuan Zeng¹, Ning Li¹*, Fei Wang¹, Canhua Jiang¹, Feng Guo¹, Xinqun Chen¹, Tong Su¹, Chunjiao Xu², Shanshan Zhang² and Changyun Fang²

Abstract

Background: In South and Southeast Asian, the majority of buccal squamous cell carcinoma (BSCC) can arise from oral submucous fibrosis (OSF). BSCCs develop in OSF that are often not completely resected, causing local relapse. The aim of our study was to find candidate protein biomarkers to detect OSF and predict prognosis in BSCCs by quantitative proteomics approaches.

Methods: We compared normal oral mucosa (NBM) and paired biopsies of BSCC and OSF by quantitative proteomics using isobaric tags for relative and absolute quantification (iTRAQ) to discover proteins with differential expression. Gene Ontology and KEGG networks were analyzed. The prognostic value of biomarkers was evaluated in 94 BSCCs accompanied with OSF. Significant associations were assessed by Kaplan-Meier survival and Cox-proportional hazards analysis.

Results: In total 30 proteins were identified with significantly different expression (false discovery rate < 0.05) among three tissues. Two consistently upregulated proteins, ANXA4 and FLNA, were validated. The disease-free survival was negatively associated with the expression of ANXA4 (hazard ratio, 3.4; \( P = 0.000 \)), FLNA (hazard ratio, 2.1; \( P = 0.000 \)) and their combination (hazard ratio, 8.8; \( P = 0.002 \)) in BSCCs.

Conclusion: The present study indicates that iTRAQ quantitative proteomics analysis for tissues of BSCC and OSF is a reliable strategy. A significantly up-regulated ANXA4 and FLNA could be not only candidate biomarkers for BSCC prognosis but also potential targets for its therapy.

Keywords: Oral submucous fibrosis, Buccal squamous cell carcinoma, Quantitative proteomic analysis, Annexin A4, Filamin-A

Background

Oral submucous fibrosis (OSF) is a chronic and insidious lesion of oral mucosa which demonstrates particularly prevalent in some South and Southeast Asian countries [1, 2]. Its histopathologic feature is characterized by the inflammatory reaction of juxta-epithelial region followed by excessive collagen deposition of the lamina propria and the underlying submucosal layer, with associated epithelial atrophy [3]. A major clinical symptom of OSF patient is trismus, a limited ability to open the mouth, which eventually impairs eating, speaking and dental care [4, 5]. Various epidemiological studies have found that the chewing of areca-nut is the main etiological factor for OSF. [6].

OSF is associated with raised risk for the oral squamous cell carcinoma (OSCC), especially buccal SCC (BSCC), because buccal mucosa is the most common region that is stimulated by chewing areca nut [7–9]. The frequency of OSF canceration has been reported to range from 3 % to 6 % [10]. The oral precancerous condition defined by WHO is that a generalized pathological...
state of the oral mucosa associated with a significantly increased risk of cancer, which accords well with OSF characteristics [8]. Meanwhile, OSF is currently a public health problem in many countries, especially in some countries of southeastern Asian [11].

The molecular mechanisms of OSF progression and oncogenesis remain unclear and may be considered complex events in the deregulated expression of multiple molecules [12]. High-throughput proteomics can perform analysis to know expression profiles for thousands of proteins and characterize the biologic behaviors of cell simultaneously, which can contribute to better understand the changes of multiple proteins related to the disease progression and identify diagnostic and prognostic biomarkers. Different proteomics studies have been successfully engaged in the biomarker discovery of oral cancer. However, it is still hard to discover unique biomarkers to predict which oral mucosal disease will progress to OSCC [13, 14].

In the present study, we analyzed normal buccal mucosa (NBM), OSF and BSCC by isobaric tags for relative and absolute quantification (iTRAQ) system with two-dimensional liquid chromatography-tandem mass spectrometry (2DLC-MS/MS) to find the biomarkers contributed to the diagnosis and prognosis of OSF and BSCC. iTRAQ can label total peptide, preserve the information of post-translational modification and make quantitative analysis of 4 tissue samples simultaneously with same experimental conditions [14, 15]. Two novel protein biomarkers identified in our study may be clinically useful for BSCC detection arising from OSF, and evaluate their prognosis values.

**Methods**

**Experimental design and analytical strategy**

Briefly, there were three consecutive phases in this study: first a discovery screen of quantitative proteomics based on iTRAQ was carried out to identify candidate biomarkers with the consistently deregulated expressing levels from NBM to OSF to BSCC, second a protein-level evaluation of promising biomarkers by western blotting and immunohistochemistry, and third a validation of the candidate biomarkers in clinical samples by a retrospective study. We received ethical approval from the Xiangya Hospital Human Research Ethics Committee. All patients included for both the biomarker discovery screen and the retrospective clinical validation study were diagnosed with a primary BSCC arising from OSF. Enrolled cases were scheduled for surgical treatment with informed consent. Meanwhile, all cases had the habit of areca-quid chewing, and no previous local treatments for oral mucosa. All histological evaluations and grading were done according to the WHO standard criteria.

**Patients and Tissue Samples**

Paired biopsies of BSCC and OSF tissue were collected from BSCC patient accompanied with OSF lesion simultaneously. For every patient, BSCC sample was taken from the surgical cancer tissue, and matched OSF sample was from the contralateral buccal mucosa. In addition, unmatched NBM tissue was procured from healthy volunteer without the habit of betel-quid chewing. Each specimen was divided into three parts: one was for pathologic review to confirm the diagnosis, while the remaining two parts were immediately snap-frozen for quantitative proteomic and western blotting analysis respectively. If a paraffin specimen was confirmed by pathologists, it would be stored for immunohistochemical analysis. Eventually, 6 NBMs, 6 OSFs and 6 BSCCs were enrolled for proteomic and western blotting analysis. Clinical and histopathologic details of enrolled cases are listed in Table 1. Ninety-four formalin-fixed paraffin-embedded BSCC specimens, which were all removed from primary BSCC patients accompanied with OSF between November 2008 to August 2013, were drawn and reconfirmed for the retrospective clinical validation study. Age, TNM grade, UICC classification, OSF and BSCC histological grade, and survival time were recorded as the clinicopathological data (Additional file 1: Table S1). All enrolled cases had the habit of areca-quid chewing. All histological evaluations were done according to the WHO standard criteria.

**Reagents and apparatus**

iTRAQ™ Reagents Kit was bought from Applied Biosystems (San Jose, CA, USA). The acetonitrile, formic acid, acetone, trypsinil, and sodium citrate buffer were from Sigma-Aldrich (California, CA, USA). The Zorbax 300SB-C18 reversed-phase column (Microm, Auburn, CA, USA), the Polysulfoethyl column (The Nest Group, Southborough, MA, USA) and QSTAR XL System (Applied Biosystem, California, CA, USA) were for 2D LC-MS/MS. Sep-Pak Vac C18 cartridges was obtained from Millipore Corporation (Minneapolis, Minnesota, USA). The rabbit polyclonal antibodies were purchased from Abcam (London, UK).

### Table 1 BSCC patients enrolled for iTRAQ quantitative proteomic analysis

| Case | Age Range (y) | BSCC Site | BSCC T-stage | BSCC Differentiation | OSF Differentiation |
|------|---------------|-----------|--------------|----------------------|-------------------|
| 1    | 30–35         | Left      | T_N_M0       | Well                 | Moderate          |
| 2    | 35–40         | Left      | T_N_M0       | Well                 | Moderate          |
| 3    | 45–50         | Right     | T_N_M0       | Well                 | Early             |
| 4    | 25–30         | Left      | T_N_M0       | Well                 | Moderate          |
| 5    | 55–60         | Right     | T_N_M0       | Well                 | Advanced          |
| 6    | 45–50         | Left      | T_N_M0       | Well                 | Advanced          |
Candidate biomarkers discovery by quantitative proteomic analysis

Protein preparation and iTRAQ labeling
The protein samples were quantitated by the Bradford method. The iTRAQ labeling was carried on according to the protocol. Briefly, 200 μg proteins were precipitated at 20 °C for 60 min. Then they were resuspended in 20 μl dissolution buffer. After reduction and alkylation, the peptides were labeled with iTRAQ regents for 60 min. Three iTRAQ regents (115, 116 and 117) were used to label the peptides of OSF, BSCC and NBM respectively. Sequentially, the samples were mixed together, and desalted by Sep-Pak Vac C18 cartridges.

2D LC-MS/MS analysis
The mixed labeling peptides were fractionated by strong cation exchange chromatography (SCX). The mixture was reconstituted with Buffer A (10 mM KH$_2$PO$_4$ in 25 % acetonitrile, PH 2.6). The mixed peptides were separated at a 500 μl/min with a gradient of 0-80 % Buffer B (Buffer B was Buffer A containing 350 mM KCl) in Buffer A for 1 h. The 215 nm and 280 nm absorbance was monitored and a total of 12 SCX fractions were got together. The fractions were dried and resuspended in 50 μl HPLC Buffer A (5 % acetonitrile, 0.1 % formic acid). Then they were loaded across the Zorbax 300 SB-C18 reversed-phase column and assessed on a QSTAR XL System with a 20 AD HPLC system. The elution flow rate was 0.3 μl/min with gradient 5 %–35 % HPLC Buffer B (98 % acetonitrile, 0.1 % formic acid) for 90 min. The scans were obtained with m/z ranges of 400–1800 for MS with up to three precursors selected from m/z 100–2000 for MS/MS.

Protein identification
The MS/MS data were searched from the International Swissprot using the Protein Pilot software 3.0 (Applied Biosystem, USA). The parameters were as follows: trypsin as enzyme, methylnethanethiosulphonate of cysteines residues as modification. Then the Paragon Algorithm followed by the ProGroup Algorithm (Applied Biosystem, USA) were used to cancel redundant hits. Parent ion accuracy, fragment ion mass accuracy, tryptic cleavage specificity, and allowance for missed cleavages were provided by Protein Pilot. The benchmark for protein identification was unused Prot-Score >1.3 (95 %) as the threshold. The relative protein expression was based on the ratio of peptides ions (115:117 or 116:115). We used the fold change ratio ≤0.5 or ≥2 to designate differentially expressed proteins ($P < 0.05$).

Bioinformatic analysis
Pathway analysis was performed by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Gene Ontology (GO) database was used to facilitate the biological interpretation of the identified protein in these studies. The differentially expressed proteins of GO were divided into 3 categories as follows: biological process (BP), molecular function (MF) and cellular component (CC).

Validation Studies
Western blotting
30 μg protein was firstly separated with 12 % SDS-PAGE, then transferred on the polyvinylidene fluoride (PVDF) membrane. After blocked, filter was incubated by the primary antibody. The secondary antibody (Santa Cruz Biotechnology, California, CA) was applied onto the filter at 1:2,000 dilutions. Samples were probed with anti-β-actin antibody (BD Biosciences, San Jose, CA) as an internal control. We used ECL system (Amersham, Buckinghamshire, UK) to visualize bands, and the Bandscan software (Glyko, Novato, CA) for the analysis of signal intensity.

Immunohistochemical evaluation
Briefly, serial 3 μm thick sections of tissue sample were mounted on silanized slides. After blocked by 3 % hydrogen peroxide, sections were incubated by primary antibodies, then by the biotinylated IgG (Santa Cruz Biotechnology, CA) for 30 min. Antigen–antibody complexes were dealt with diaminobenzidine (DAB). Then slides were counterstained by Mayer’s Hematoxylin. The immunoreactivity of candidate biomarkers were assessed by counting the number of positive cells. We considered that ≥10 % positive cells were graded as immunopositive. For every sample, the result of immunoreactive staining was evaluated by two observers blinded for the data.

Clinical and prognostic validation in a retrospective case study
Cohort for the retrospective study
Ninety–four primary BSCCs accompanied with OSFs were immunohistochemically stained for biomarker candidates.

Follow-up study
All patients undergoing surgery were followed up. The time to death or recurrence was recorded in detail periodically. Disease free survival time was recorded from the time of histological diagnosis to the time of the last follow-up. If a patient died or was found recurrent, survival time was censored at that time. Overall survival can not be regarded as a separate parameter, because among the patients lost to follow up, the death number could not be ascertained. Only disease free survival of the patients was recorded.

Statistical Analysis
Statistical analysis of western blotting data was dealt with Student’s $t$ test. The relationship between the
expression of proteins and clinicopathological parameters was evaluated by Chi-Square or Fisher's exact test. Follow-up studies were evaluated by Kaplan–Meier and Cox’s Proportional Hazards test. \( P < 0.05 \) was regarded as significant. All statistical analysis was performed by SPSS 19.0.1 software.

**Ethics statement**
This study has been approved by the Ethics Board of Xiangya Hospital, which was also in accordance with the 1975 Helsinki Declaration. All patients had written the informed consent. Human samples were performed anonymously.

**Results**

**Biomarker discovery screen**
A total of 1998 proteins were identified from 14237 peptides among three tissues, based on the Unused ProtScore >1.3 (95 %) with at least one peptide above the 95 % confidence. 71.7 % proteins were with at least two peptides. And 56.2 % proteins were identified with three or more (Additional file 2: Table S2). Compared NBM 117 labeled, 90 proteins were up-regulated and 46 were down-regulated significantly in OSF 115 labeled. Meanwhile, between BSCC 116 labeled and OSF 115 labeled, 91 differential proteins were obtained, which contained 51 up-regulated and 40 down-regulated proteins in BSCC. Most importantly, in total of 30 proteins were identified with significantly different expression among three tissue types (Table 2). Among them, 2 candidate proteins (Annexin A4, ANXA4; Filamin-A, FLNA) were consistently upregulated, and one protein (Fibrinogen alpha chain precursor, FGA) was consistently down-regulated from NBM to OSF to BSCC.

**KEGG pathway analysis**
Thirty--two signaling pathways among three tissue types were identified using KEGG database (Fig. 1a). The differentially expressed protein clusters could be assigned into numerous subcategories including the systemic lupus erythematosus, antigen processing and presentation, arginine and proline metabolism, focal adhesion, tyrosine metabolism, and so on. There were cross-talks among these pathways, as one protein might participate in several signaling pathways. Alcohol dehydrogenase 4 (ADH4) was involved in the most pathways (9 pathways) and Systemic lupus erythematosus pathway accounted for the most differentially expressed proteins (15 proteins) (Additional file 3: Table S3).

**GO analysis**
These differentially expressed proteins were grouped into 72 (45.28 %) GO terms based on BP GO terms. The most enriched BP GO terms included cell redox homeostasis, interspecies interaction between organisms and oxidation reduction. There were 52 (32.7 %) GO terms identified by MF classification, and 35 (22.01 %) GO terms identified by CC classification. The top component for MF were protein binding, which consisted of 7 proteins. While the top component for CC were cytoplasm, which also consisted of 7 proteins (Additional file 4: Table S4).

Table 2 Total 30 differentially expressed proteins among three tissue types

| Protein | Symbol | Accession | BSCC/OSF (116:115) | OSF/NBM (115:117) |
|---------|--------|-----------|--------------------|--------------------|
| ANXA4   | IPI00872780.1 | 4.8305881 | 2.051162243 |
| MFAP4   | IPI00793751.1 | 0.033419501 | 5.7543993 |
| GATM    | IPI00792191.1 | 3.250873089 | 0.343557954 |
| CES1    | IPI0067801.2 | 11.16862965 | 0.108642563 |
| PSME1   | IPI00479722.2 | 3.837071896 | 0.296483129 |
| KRT19   | IPI00479145.2 | 0.197696999 | 18.03017807 |
| HIST1H4I| IPI00453473.6 | 0.04786301 | 2.582260132 |
| VM      | IPI00418471.6 | 0.296483099 | 2.55858882 |
| FLNA    | IPI00333541.6 | 3.83707315 | 2.128139019 |
| KRT7    | IPI00306959.10 | 0.246603906 | 4.28545268 |
| COL1A2  | IPI00304962.3 | 0.343558013 | 2.167704105 |
| COL1A1  | IPI00297646.4 | 0.27289781 | 2.884031534 |
| GPID1   | IPI00295777.6 | 0.251188581 | 4.055085182 |
| LTB4D1  | IPI00292657.3 | 3.630779982 | 0.405508548 |
| COL6A1  | IPI00291136.4 | 0.366437614 | 2.8319205 |
| MPO     | IPI00236556.1 | 0.205116197 | 9.54925804 |
| GOT1    | IPI00219029.3 | 0.465586096 | 8.709635735 |
| ADH4    | IPI00218899.5 | 0.2679167986 | 5.649369717 |
| GSTM1   | IPI00218831.4 | 0.2051162004 | 9.54925804 |
| CALM1   | IPI00075248.11 | 0.35318321 | 13.5519419 |
| CTSG    | IPI00028064.1 | 0.251188606 | 5.105050087 |
| HSP90B1 | IPI00027230.3 | 2.83139205 | 0.310455948 |
| PDIA4   | IPI00025252.1 | 3.40408206 | 0.237684026 |
| TF      | IPI00022463.1 | 2.754290699 | 0.322106868 |
| APCS    | IPI00022391.1 | 0.110662401 | 4.830587864 |
| FGA     | IPI000021885.1 | 0.387257606 | 0.432513833 |

The proteins written with bold words were the same differentially expressed proteins among three tissue types (from BSCC to OSF to NBM)
Fig. 1 (See legend on next page.)
Initial evaluation of candidate biomarkers
ANXA4 and FLNA were selected as the candidate biomarkers for BSCC arising OSF lesion because the two showed consistently upregulated from NBM to OSF to BSCC.

Western blotting
Staining intensities of ANXA4 and FLNA in BSCC were all significantly higher than OSF and NBM with a consecutively upregulated trend from NBM to OSF to BSCC (P = 0.002 and 0.001, respectively). Representative results were presented in Fig. 2a.

Immunohistochemistry evaluation
In Fig. 2b, no detectable expression of ANXA4 was found in NBM, while OSF exhibited brown cytoplasm staining mainly limited to the spinous epithelial layer, and sometimes keratinocyte layer together. While in the BSCC, ANXA4 protein showed intensively staining of the cytoplasm in cancer cell. The positive expression of ANXA4 in BSCC was significantly higher than OSF (P = 0.008), while positive ANXA4 of OSF was significantly higher than NBM (P < 0.0001).

In Fig. 2c, very weak expression of FLNA was shown in NBM. However, OSF exhibited brown cytoplasm staining mainly limited to the lower spinous epithelial layer and basal cell layer. While in the BSCC, FLNA protein showed intensively staining of the cytoplasm in cancer cell. The positive expression of FLNA in BSCC was significantly higher than OSF (P = 0.004), while positive FLNA expression in OSF tissues was significantly higher than NBM tissues (P = 0.01).

Correlation of candidate biomarkers with clinicopathological parameters
As shown in Table 3, positive ANXA4 and FLNA were significantly related to T stage (P = 0.017 and P = 0.042, respectively). Positive ANXA4 showed a forward relationship with N stage (P = 0.001), while positive FLNA showed an inverse trend with N stage (P = 0.017). Meanwhile, there was a statistically significant relationship between positive ANXA4 and tumor stage (P = 0.004), while no association was found in other parameters.

Association of candidate biomarkers with patient prognosis
Seventy-three of 94 BSCC patients could be followed up. Patients were monitored for a period of median 22 months and a maximum of 58 months. Kaplan-Meier curves revealed that the disease-free survival was associated significantly with the negative expression of ANXA4 and FLNA (P = 0.000 and P = 0.000, respectively) in BSCCs in Fig. 3. Hazard ratios calculated by univariate Cox regression analysis, were 3.4 (95 % confidence interval, 2.2–7.5; P = 0.004) for ANXA4 and 2.1 (95 % confidence interval, 1.7–5.5; P = 0.0036) for FLNA. ANXA4 and FLNA immunostaining data were combined to form one BSCC group with positive ANXA4 and FLNA expression, and another group with negative ANXA4 and FLNA. This classification showed an association between patients with negative ANXA4 and FLNA and disease-free survival (P = 0.002) and has a superior prognostic power with a hazard ratio of 8.8 (95 % confidence interval, 3.0–32.6; P = 0.005).

Discussion
Some previous studies have identified a large number of differentially expressed biomarkers at the mRNA level between normal oral mucosa and OSCC or OSF tissues respectively [16–19]. Meanwhile lots of protein biomarkers between normal oral mucosa and OSCC have also been found for long time. However, few studies focused the differentially expression of protein biomarkers between NBM and OSF. The present study is the first comprehensive research on proteins with differential expression among NBM, OSF and BSCC arising from OSF by using the iTRAQ shot-gun proteomic approach [20]. In this present study, we used whole tissue rather than microdissected tissue cells for our proteomics analysis. We think that whole tissue could have the ability of reflecting the tumor microenvironment accurately, which is believed to determine whether cancer can spread through epithelial-mesenchymal interactions (EMT) [21]. However, the main limitation for whole tissue in proteomics analysis is the cell heterogeneity of different tissues.

By iTRAQ proteomic approach, we identified in total 30 unique proteins from NBM to OSF to BSCC. Among the deregulated proteins, some were previously reported to be correlated with the pathogenesis of OSF, such as KRT19 [16], COL1A2 [22], GSTM1 [23], VIM; [24] some were not yet observed in OSF but within OSCC, for instance PSM1 [25], FLNA [26], GOT1 [27], GSTM1; [28] and some were not reported in any study on both OSF and OSCC. In addition, a large number of proteins identified in the previous reports were not found in our present study. The discordance between
them may be explained partially by the limited dynamic range of iTRAQ [15]. Moreover, the difference of races and region distributions, the different processed methods of areca nut, as well as the different procedure of tissue collection and management may contribute to the distinction among various laboratories.

The location, function and regulation of the differentially expressed proteins can be better and easier to understand by bioinformatics analysis. The results of bioinformatic analysis showed that most consistently expressed proteins were randomly regulated proteins during OSF pathogenesis and carcinogenesis, because most of them were found in the discrete interaction networks. The top 5 GO components showed that the differentially expressed proteins in the present study were located mainly in cytoplasm with the protein binding function, which contained cell redox homeostasis, interaction between organisms, oxidation reduction and

Fig. 2 Initial validation of two candidate biomarkers. a Western blot of ANXA4 and FLNA in the samples of NBM and paired BSCC and OSF, as well as their corresponding quantifications. b representative immunohistochemical staining for ANXA4. Negative expression of ANXA4 in NBM, brown cytoplasm staining limited to the spinous epithelial layer of OSF, and intensively staining of the cytoplasm in BSCC cell nest. c representative immunohistochemical staining for FLNA. Weak expression in NBM samples, brown cytoplasm staining limited to the lower spinous epithelial layer and basal cell layer of OSF, and intensively staining of the cytoplasm in BSCC cell.
tissue regeneration. The top regulation network in the study, systemic lupus erythematosus pathway, indicated that immunological reaction might be the most important factor during the pathogenesis and carcinogenesis of OSF lesion, which is in agreement with the conclusions of our previous study and other research groups [16, 29–31].

Notable proteins in our present study were three consistently deregulated proteins from NBM to OSF to OSCC, which were related to the mechanisms of the progression of OSCC arising from OSF. Two consistently upregulated proteins, ANXA4 and FLNA, were selected as the candidate biomarkers because we considered that the progress of OSF pathogenesis and carcinogenesis could be blocked effectively through interfering their upregulated expression. They would be promising targets for molecular therapy of OSF and OSCC.

The annexins, a multigene family of calcium-dependent phospholipid-binding proteins, have some special functions including the aggregation of vesicles and regulation of ion channels as well as roles in the regulation of cell cycle, cell signal and cell differentiation [32]. Meanwhile, annexins have been found in the processes of several disease, involving in inflammation and several neoplasia [33]. Of all annexins, ANXA4 was related to the loss of cell adhesion, and play important roles in apoptosis, carcinogenesis, chemoresistance, migration and invasion of cancer cells [34]. It binds phospholipids through the Ca-dependent manner and is located in the nucleus, cytoplasm, or membrane of cell [35]. ANXA4 was overexpressed in various primary clinical epithelial tumors, such as renal cancer [34], ovary cancer [35], gastric cancer [36], colorectal cancer [37], breast cancer [38], laryngeal carcinoma [38], pancreatic cancer [38, 39]. Its overexpression could enhanced significantly with the tumor stage and poorer prognosis [39], and be related to promote cell migration in a model tumor system [37]. These results are correlates with our observation in the present study that increased ANXA4 expression is associated with BSCC stage and poor prognosis. ANXA4 can form protein kinase C complexes. Moreover, it is found that at least 10 isoforms of protein kinase C have roles in the progression of cancers, including OSCC [40]. It could be found association with protein kinase C that ANXA4 has a vital effect on the BSCC pathogenesis. All these findings indicate that ANXA4 might have a vital role in the BSCC progression and migration. Meanwhile, ANXA4 expression was first identified in OSF tissues, which further proved the potential carcinogenic capacity of OSF.

FLNA is a type of actin filament cross-linking protein that participates in cytoskeletal rearrangement [41]. By its scaffolding function, FLNA can interact with more than 90 functionally diverse binding partners to regulate cellular functions and processes [42, 43]. The FLNA-deficient cells can not polarize and move because of their unstable surfaces which can continuously expand and contract circumferential blebs [44]. The orthogonal networks of FLNA have the active and reversible organizational properties, which can protect cell from various shear stresses [45]. In the present study, we firstly found that FLNA was positively expressed in OSF. Obviously, for oral mucosa cells in OSF patients, persistently mechanical shear stress caused by areca-nut chewing could be the key reason for the upregulated FLNA as a protective reaction of oral mucosa. Mis-regulation of FLNA plays a critical role in DNA double strand breaks response for the initiation of tumorigenesis [46]. Meanwhile, because of its ability to control cell mobility, cell-ECM interactions, cell signaling, and DNA damage response, FLNA could be regarded as a novel biomarker for the diagnosis and outcome prediction of cancer.
Meanwhile, it has been reported that there was the correlation of increased FLNA expression in different stages of various cancer types and patient outcomes, such as colorectal cancer [47], pancreatic cancer [48], gliomas [49], prostate cancer [50] and salivary gland adenoid cystic carcinoma [51]. In the present study, we employed quantitative proteomic analysis to assess the FLNA expression and localization. Our data also illustrated that the expression of FLNA was increased in BSCC, and a poor survival index for patients with BSCC have high FLNA levels. So it is conceivable that the FLNA level in BSCC can be developed as a promising biomarker for the outcome prediction of BSCC.

Conclusion
Taken together, our proteome analysis has revealed a number of potential biomarkers among NBM, OSF and BSCC. Meanwhile, of these, ANXA4 and FLNA seem to
have large prognostic value for patient survival, which may represent OSF and BSCC biomarkers and potential targets for therapeutic intervention. To our knowledge, although ANXA4 and FLNA has been reported on the carcinogenic roles of some tumors, no studies has been published on their expression in BSCC arising from OSF. However, more large-scale, prospective multicenter trials should be carried out further elucidate their value in the clinic, and the roles of two biomarkers in BSCC development and invasion are in need of further study.

Acknowledgements
This research was supported by the Department of Oral and Maxillofacial Surgery at Xiangya Hospital, Central South University, China.

Funding
This work was supported by the National Natural Sciences Foundation of China (grant no. 81000445).

Availability of data and materials
The datasets supporting the conclusions of this article are available in the FigShare repository [unique persistent identifier and hyperlink to datasets in https://figshare.com/s/cc1f524ba26e5b7e2441b] and the DOI number is 10.6084/m9.figshare.3405691.

Authors’ contributions
NL conceived of the study, and participated in its design and coordination and helped to draft the manuscript. WL carried out the proteomics studies and bioinformatic analysis. LZ and FW carried out the immunoassays and immunohistochemical evaluation. CJ, FG, XQ, SZ and CF participated in revising MS critically for important intellectual content. TS and CX participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
This study has the approval of the Ethics Board of Xiangya Hospital and is also in accordance with the Helsinki Declaration of 1975. Written informed consent was obtained from every patient. All human tissues were processed anonymously.

Author details
1Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University, No. 88, Xiangya Road, Changsha, China. 2Department of Oral Medicine, Xiangya Hospital, Central South University, No. 88, Xiangya Road, Changsha, China.

Received: 31 August 2015 Accepted: 28 July 2016 Published online: 02 August 2016

References
1. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking, and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med. 1995;24:450–9.
2. Tilkaratne WM, Klinikowski MF, Saku T, Peters TJ, Wamakulasuriya S. Oral submucous fibrosis: review on etiology and pathogenesis. Oral Oncol. 2006;42:561–8.
3. Issac U, Issac JS, Ahmed KN. Histopathologic features of oral submucous fibrosis: a study of 35 biopsy specimens. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:536–60.
4. Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis—a collagen metabolic disorder. J Oral Pathol Med. 2005;34:321–8.
5. Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966;22:764–79.
6. Murti PR, Bhonsie RB, Pindborg JJ, Daftary DK, Gupta PC, Mehta FS. Malignant transformation rate in oral submucous fibrosis over a 17-year period. Community Dent Oral Epidemiol. 1985;13:340–1.
7. Auluck A, Rosin MP, Zhang L, Sumanth KN. Oral submucous fibrosis, a clinically benign but potentially malignant disease: report of 3 cases and review of the literature. J Can Dent Assoc. 2008;74:335–40.
8. World Health Organization. Guide to the epidemiology and diagnosis of oral mucosal diseases and conditions. Community Dent Oral Epidemiol. 1980;8:261–2.
9. Scully C, Bagan J. Oral squamous cell carcinoma: an overview. Oral Oncol. 2006;42:561–8.
10. Trivedy CR, Craig G, Wamakulasuriya S. The oral health consequences of chewing areca nut. Addict Biol. 2002;7:115–25.
11. Jacob BJ, Straf K, Thomas G, Ramdas K, Mathew B, Zhang ZF. Betel quid without tobacco as a risk factor for oral precancers. Oral Oncol. 2004;40:697–704.

Abbreviations
2-DE, two-dimensional gel electrophoresis; 2DLC-M/SMS, two-dimensional liquid chromatography-tandem mass spectrometry; ADH4, Alcohol dehydrogenase 4; ANXA4, Annexin A4; AP, biological process; BSCC, buccal squamous cell carcinoma; CC, cellular component; DAB, diaminobenzidine; EMT, epithelial-mesenchymal interactions; FGA, Fibrogenin alpha chain precursor; FLNA, Filamin-A; GO, Gene Ontology; ICAT, isotope-encoded affinity tags; ITMA, isotopic tagging mass analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; MF, molecular function; NBM, normal oral mucosa; OSCC, oral squamous cell carcinoma; OSF, oral submucous fibrosis; PVDF, polyvinylidine fluoride; SCX, strong cation exchange chromatography; SILAC, stable isotope labeling by amino acids in cell culture.
12. Lin SC, Chen YJ, Yao SY, Hung MT, Lin CH, Yang SC, et al. Chromosomal alterations in beta3-associated oral squamous cell carcinoma and their relation to clinical parameters. Oral Oncol. 2002;38:266–73.

13. Miele C, Ernst G, Winkler R, Schimmel M, Kussmann JP, Wittkindt C. Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: identification of threonin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics. 2009;9:239–201.

14. Ralhan R, DeSouza LV, Matha A, Tripathi SC, Ghany S, Data Gupta S. iTRAQ Multidimensional Liquid Chromatography and Tandem Mass Spectrometry-Based Identification of Potential Biomarkers of Oral Epithelial Dysplasia and Novel Networks between Inflammation and Premalignancy. J Proteome Res. 2009;8:290–9.

15. WuWulfshef JD, Loita LA, Petriccin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.

16. Ning L, Xinchun J, Yanjia H, Chunjiao X, Yaozhi G, Xiaohuan Z. Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:2499–509.

17. Kao WB, Shieh YD, Hsia YJ, Shieh TY. The micro-array analysis of genetic change and proteins identification of oral squamous fibrosis. Int J Oral Maxillofac Surg. 2005;34:139.

18. Oken MD, Winkler AE, Kanchi KL, Chalvendra V, Law JH, Rickert CG, et al. A transscripting cross-species conserved in the genomic landscape of mouse and human oral cancer identifies a transcriptional signature predicting metastatic disease. Clin Cancer Res. 2011;17:2837–44.

19. Vincent VK, Anwar A, Karen LP, Cheong SC, Yang JH, Pradep PJ, et al. Genome wide analysis of chromosomal alterations in oral squamous cell carcinomas revealed over expression of MFGM and ADAM9. PLoS ONE. 2013;8:e54705.

20. Wu WW, Wang G, Baek SJ, Shen RF. Comparative Study of Three Proteomic Quantitative Methods, DICE, cCAT, and iTRAQ, Using 2D Gefer LC-MALDI TOF/TOF. J Proteome Res. 2006;5:651–68.

21. Sausville EA. The challenge of pathway and environment-mediated drug resistance. Cancer Metastasis Rev. 2001;20:117–22.

22. Chiu CJ, Chang ML, Chiang CP, Hahn LJ, Hsieh LL, Chen CJ. Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002;11:646–53.

23. Deepa A, Shalini G, Deepti A, Prakash G, Mohit A. Role of GSTM1 and GSTT1 Polymorphism: Susceptibility to Oral Submucous Fibrosis in the North Indian Population. Oncology. 2010;79:181–6.

24. Meghanand TN, Anjai S, Rajiv SD. Immunohistochemical Analysis of Vimentin in Oral Submucous Fibrosis. J Cancer Epidemiol. 2013;2013:549041.

25. Saffil AK, Afza S, Rooh BZ, Ching C, Mariati AR. Comparative proteomics analysis of oral cancer cell lines: identification of cancer associated proteins. Proteome Sci. 2014;12:5.

26. Daniela CG, Mariana RZ, Rebeca K, Sami Y, Romelina RD, Anmelize ZA, et al. Integrated Proteomics: Identifiers Up-Regulated Focal Adhesion-Mediated Proteins in Human Squamous Cell Carcinoma in an Orthotopic Mouse Model. PLoS ONE. 2016;4:e92808.

27. Fernandez MS, Rebeca K, Sami Y, Daniela CG, Lucas M, Michelle A, et al. ADAM17 mediates OSCC development in an orthotopic mouse model. Mol Cancer. 2014;13:24.

28. Rosy M, Sankar KG, Javed HC, Arini S, Kavita S, Marine H, et al. Mitochondrial DNA Copy Number and Risk of Oral Cancer: A Report from Northeast India. PLoS ONE. 2013;8:e57771.

29. Li N, Hu Q, Jiang C, Guo F, Munnee K, Jian X, et al. Cys-X-Cys ligand 9 might be an immunological factor in the pathogenesis of oral submucous fibrosis and its concomitant oral lichenoid lesion. Clin Oral Investig. 2013;17:1215–21.

30. Rajendran R, Deepthi K, Nooh N, Arini S, o8B1 integrin-dependent cell sorting dictates T-cell recruitment in oral submucous fibrosis. J Oral Maxillofac Pathol. 2011;15:72–7.

31. Jeng JH, Wang YJ, Chiang BL, Lee PH, Chan CP, Ho YS, et al. Roles of keratinocyte inflammation in oral cancer: regulating the prostaglandin E2, interleukin-6 and TNF-alpha production of oral epithelial cells by areca nut extract and arecoline. Carcinogenesis. 2003;24:1301–15.

32. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signaling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449–61.

33. Hayes MJ, Moss SE. Annexins and disease. Biochem Biophys Res Commun. 2004;322:1166–70.

34. Zimmermann U, Babalosov S, Giebel J, Teller S, Junker H, Schmid D, et al. Increased expression and altered localization of annexin IV in renal clear cell carcinoma: a possible role in tumour dissemination. Cancer Lett. 2004;209:111–8.

35. Kim A, Serada S, Enomoto T, Naka T. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets. 2010;14:963–71.

36. Lin LL, Chen CN, Lin WC, Lee PH, Chang KJ, Lai YP, et al. Annexin A4: a novel molecular marker for gastric cancer with Helicobacter pylori infection using proteomics approach. Proteomics Clin Appl. 2008;2:519–34.

37. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer. 2008;99:426–33.

38. Deng S, Wang J, Hou L, Li J, Chen G, Jing B, et al. Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett. 2013;5:107–12.

39. Steb B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenborg T, et al. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunohistochemical validation. J Proteome Res. 2009;8:1647–56.

40. Lai KC, Liu CJ, Chang KW, Lee TC. Depleting IFIT2 mediates atypical PKC signaling to enhance the migration and metastatic activity of oral squamous cell carcinoma cells. Oncogene. 2013;32:3686–97.

41. Savoy RM, Ghosh PM. The dual role of annexin A in cancer: can’t live with (too much of) it, can’t live without it. Endocr Related Cancer. 2013;20:341–56.

42. Nakamura F, Stossel TP, Hartwig JH. The annexins: organizers of cell structure and function. Cell Adh Migr. 2011;5:160–9.

43. Razinia Z, Makela T, Ylanne J, Calender DA. Filamins in mechanosensing and signaling. Ann Rev Biophys. 2012;41:227–46.

44. Plevatis P, Stojanovic A, Gong H, Chisti A, Welch E, Du X. A molecular switch that controls cell spreading and retraction. J Cell Biol. 2007;179:553–65.

45. Kasa KE, Nakamura F, Hu S, Kollmannsberger P, Bonakdar N, Fabry B, et al. Annexin A is essential for active cell stiffening but not passive stiffening under external force. Biophys J. 2009;96:4326–35.

46. Velkova A, Canahal MA, Johnson JQ, Tavtigian SV, Monteiro AN. Identification of Annexin A as a BRCA1-interacting protein required for efficient DNA repair. Cell Cycle. 2010;9:1421–33.

47. Uhlen M, Björling E, Agaton C, Szijártó CA, Aminni B, Andersen E, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4:1920–32.

48. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003;63:2649–57.

49. Bedolla RG, Wang Y, Asuncion A, Chamiie K, Siddiqui S, Mudryj MW, et al. Nuclear versus cytoplasmic localization of Annexin A in prostate cancer. Immunohistochemical correlation with metastases. Clin Cancer Res. 2009;15:788–96.

50. Sun GG, Lu YF, Zhang J, Hu WN. Annexin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumour Biol. 2014;35:38291–3826.

51. Frierson HF, El-Naggar AK, Welsh JB, Sapinlos LM, Su AI, Cheng J, et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol. 2002;161:1315–23.